⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IONS News
Ionis Pharmaceuticals, Inc. Common Stock
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
prnewswire.com
IONS
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ionis Pharmaceuticals, Inc. (IONS) and Encourages Shareholders to Learn More About the Investigation
accessnewswire.com
IONS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
accessnewswire.com
IONS
Form 8-K
sec.gov
IONS
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
businesswire.com
IONS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
globenewswire.com
IONS
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
globenewswire.com
AZN
LLY
NVO
PFE
AMGN
BMY
JNJ
REGN
VKTX
ZETA
CRSP
IONS
AXSM
MRK
GSK
SNY
IMUX
BMEA
ALKS
ALT
AARD
NOV
CARM
CRIS
LPCN
GILD
REG
SPRO
ABSI
ALZN
ANVS
BV
ARCL
ACIU
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS
globenewswire.com
IONS
RECORDATI: SOLID MOMENTUM OF THE GROUP CONTINUES FIRST HALF 2026. NET REVENUE +6.6%, EBITDA +8.8%, ADJUSTED NET INCOME +6.7%
globenewswire.com
MRNA
IONS
Ionis Pharmaceuticals, Inc. (IONS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
accessnewswire.com
IONS